Nanjing Vazyme Biotech Co., Ltd

SHSE:688105 Stok Raporu

Piyasa değeri: CN¥9.0b

Nanjing Vazyme Biotech Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 1/6

Nanjing Vazyme Biotech's earnings have been declining at an average annual rate of -42%, while the Biotechs industry saw earnings growing at 5.9% annually. Revenues have been growing at an average rate of 5.5% per year. Nanjing Vazyme Biotech's return on equity is 0.6%, and it has net margins of 1.7%.

Anahtar bilgiler

-42.0%

Kazanç büyüme oranı

-77.6%

EPS büyüme oranı

Biotechs Sektör Büyümesi11.3%
Gelir büyüme oranı5.5%
Özkaynak getirisi0.6%
Net Marj1.7%
Son Kazanç Güncellemesi30 Sep 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Nanjing Vazyme Biotech Co., Ltd's (SHSE:688105) 45% Price Boost Is Out Of Tune With Revenues

Oct 08
Nanjing Vazyme Biotech Co., Ltd's (SHSE:688105) 45% Price Boost Is Out Of Tune With Revenues

Is Nanjing Vazyme BiotechLtd (SHSE:688105) Using Debt In A Risky Way?

Jun 26
Is Nanjing Vazyme BiotechLtd (SHSE:688105) Using Debt In A Risky Way?

Nanjing Vazyme Biotech Co.,Ltd's (SHSE:688105) Shares Climb 31% But Its Business Is Yet to Catch Up

Mar 06
Nanjing Vazyme Biotech Co.,Ltd's (SHSE:688105) Shares Climb 31% But Its Business Is Yet to Catch Up

Gelir ve Gider Dağılımı

Nanjing Vazyme Biotech nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

SHSE:688105 Gelir, gider ve kazançlar (CNY Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
30 Sep 241,40324720307
30 Jun 241,36426714309
31 Mar 241,285-15703324
31 Dec 231,286-71702339
30 Sep 232,133-232843373
30 Jun 232,520-101903411
31 Mar 232,896112917410
31 Dec 223,569594911396
30 Sep 222,885878730352
30 Jun 222,663900663303
31 Mar 222,302773587263
31 Dec 211,869678511230
30 Sep 211,715767432188
31 Dec 201,564822290126
31 Dec 192682614462
31 Dec 1817119353

Kaliteli Kazançlar: 688105 has a large one-off gain of CN¥185.5M impacting its last 12 months of financial results to 30th September, 2024.

Büyüyen Kar Marjı: 688105 became profitable in the past.


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: 688105's earnings have declined by 42% per year over the past 5 years.

Büyüme Hızlandırma: 688105 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Kazançlar vs. Sektör: 688105 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (0.08%).


Özkaynak Getirisi

Yüksek ROE: 688105's Return on Equity (0.6%) is considered low.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin